Hematology and Oncology Book

http://www.fpnotebook.com/

FondaparinuxAka: Arixtra, Factor Xa Inhibitor

Advertisement

  1. Mechanism
    1. Heparin derivative
    2. Binds activated factor X (Factor Xa)
  2. Indications: Orthopedic Perioperative DVT Prophylaxis
    1. Hip Fracture
    2. Hip replacement
    3. Knee replacement
  3. Contraindications (due to bleeding risk)
    1. Severe renal Impairment
    2. Weight less than 110 pounds
  4. Dosing
    1. Prophylaxis: DVT
      1. Arixtra 2.5 mg SQ daily
    2. Therapeutic: Bridging for DVT or PE to Warfarin
      1. Weight <50 Kg: 5 mg SQ daily
      2. Weight 50-100 Kg: 7.5 mg SQ daily
      3. Weight >100 Kg: 10 mg SQ daily
  5. Complications
    1. Bleeding
      1. Similar safety to Low Molecular Weight Heparin
    2. Spinal thrombosis with risk of paralysis
      1. Associated with concurrent spinal anesthetic
  6. References
    1. Eriksson (2001) N Engl J Med 345:1298

fondaparinux (C1098510)

ConceptsCarbohydrate (T118) , Pharmacologic Substance (T121)
MSHC438268
Englishfondaparinux, FONDAPARINUX PREPARATION
Spanishfondaparinux
Parent ConceptsAnticoagulants (C0003280), Unclassified Ingredients (C1372954), Selective factor Xa inhibitor (C1272716)
SourcesLNC, MSH, NDFRT, RXNORM, SCTSPA, SNOMEDCT, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Arixtra (C1099665)

ConceptsCarbohydrate (T118) , Pharmacologic Substance (T121)
MSHC438268
EnglishArixtra, Sanofi brand of fondaparinux sodium, Sanofi Synthelabo brand of fondaparinux sodium
SourcesMSH, NCI, PDQ, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree